Novartis Ag (NVSEF) Common Equity (2009 - 2025)

Novartis Ag has disclosed Common Equity across 13 years of filings, most recently posting $46.5 billion for Q4 2025.

• Common Equity for Q4 2025 came in at $46.5 billion, up 5.68% year-over-year; the trailing twelve-month figure through Dec 2025 was $46.5 billion (up 5.68% YoY), and the FY2025 annual result was $46.5 billion, up 5.68% from the prior year.
• Common Equity came in at $46.5 billion for Q4 2025 at Novartis Ag, up from $42.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $67.8 billion in Q4 2021 to a low of $41.9 billion in Q2 2024.
• The 5-year median for Common Equity is $49.3 billion (2023), against an average of $51.8 billion.
• Across the five-year window, Common Equity surged 4879.56% in 2021 and fell 21.33% in 2023, its largest moves.
• Novartis Ag's Common Equity stood at $67.8 billion in 2021, then retreated by 12.38% to $59.4 billion in 2022, then declined by 21.33% to $46.8 billion in 2023, then fell by 5.78% to $44.0 billion in 2024, then rose by 5.68% to $46.5 billion in 2025.
• The last three Common Equity figures came in at $46.5 billion (Q4 2025), $42.1 billion (Q2 2025), and $44.0 billion (Q4 2024), per Business Quant data.